

<b>Subject:</b>	<b>Research and Development Quarterly Performance Report – Q3 2021/22</b>	<b>Date:3<sup>rd</sup> February 2022</b>		
<b>Prepared By:</b>	Alison Steel, Head of Research and Innovation			
<b>Approved By:</b>	Elizabeth Gemmill, Research and Innovation Director			
<b>Presented By:</b>	Alison Steel, Head of Research and Innovation			
<b>Purpose</b>				
To present the Research and Innovation Quarterly Performance Report  Update and assurance on performance KPI's and financial position  Update on recovery and growth of the SFH research portfolio and research priorities for 21/22			<b>Decision</b>	
			<b>Approval</b>	
			<b>Assurance</b>	X
<b>Strategic Objectives</b>				
<b>To provide outstanding care</b>	<b>To promote and support health and wellbeing</b>	<b>To maximise the potential of our workforce</b>	<b>To continuously learn and improve</b>	<b>To achieve better value</b>
X		X	X	X
<b>Overall Level of Assurance</b>				
	<b>Significant</b>	<b>Sufficient</b>	<b>Limited</b>	<b>None</b>
		X		
<b>Risks/Issues</b>				
<b>Financial</b>	<ul style="list-style-type: none"> <li>Confirmed £752,652.04 EMCRN 2021/22 budget</li> <li>Commercial income for re-investment £102,025.82 in Q3 2021/22</li> </ul>			
<b>Patient Impact</b>	<ul style="list-style-type: none"> <li>1049 participants recruited into research studies, 648 in to UPH studies</li> </ul>			
<b>Staff Impact</b>	<ul style="list-style-type: none"> <li>Collaboration with Nottingham Trent University to support development of clinical academic careers and research exposure for clinical staff</li> </ul>			
<b>Services</b>	<ul style="list-style-type: none"> <li>Support Clinical Divisions with research engagement</li> </ul>			
<b>Reputational</b>	<ul style="list-style-type: none"> <li>Retain a strong reputation for research delivery enhanced by the breadth of UPH delivered at SFH</li> <li>Leading the way with collaboration with GP practises to increase Research opportunities in Mansfield and Ashfield, Newark and Sherwood. Secondment placement to commence February 2022.</li> </ul>			
<b>Committees/groups where this item has been presented before</b>				
None				
<b>Executive Summary</b>				
<b>Performance Metrics</b>				
<ul style="list-style-type: none"> <li>1049 participants recruited into research studies compared to 2468 Q3 20/21, 62 studies on the SFH portfolio</li> <li>Confirmed £752,652.04 EMCRN 2021/22 budget.</li> <li>Commercial income at £102,025.82</li> </ul>				
<b>Research Priorities</b>				
<ol style="list-style-type: none"> <li>Develop a balanced R&amp;I function that can deliver Covid-19 Research alongside a healthy portfolio of non UPH studies.</li> <li>Work with and support Clinical Divisions with research engagement</li> </ol>				

3. Further develop partnership with Nottingham Trent University to support development of clinical academic careers and research skills for clinical staff relevant to their role; including training, mentoring and research idea development
4. Work closely with the transformation team to develop a mechanism to capture and cultivate innovation with a focus on commercialisation and intellectual property
5. Develop an R&I plan across the system - SFH representation on the ICS R&I Executive Group as key contributors to the planning and coordination of services, ensuring equal access to research across the region.
6. Focus on working in partnership with GP practices in Mansfield and Ashfield, Newark and Sherwood. PANORAMIC study in set up that will enable us to work collaboratively.
7. Creating a research environment at SFH which can deliver digitally enabled trials
8. Developing the Clinical Research Facility.